Cargando…
Self-limited membranous nephropathy after intravitreal bevacizumab therapy for age-related macular degeneration
BACKGROUND: Monoclonal antibodies targeting vascular endothelial growth factor (VEGF), such as bevacizumab, are administered intravitreally for the treatment of wet or exudative age-related macular degeneration (ARMD). Systemic use of bevacizumab has been linked to a wide range of renal adverse effe...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Society of Diabetic Nephropathy Prevention
2017
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5607973/ https://www.ncbi.nlm.nih.gov/pubmed/28975092 http://dx.doi.org/10.15171/jnp.2017.23 |